Uttar Pradesh-based Zeon Lifesciences is ramping up its offerings in the botanicals, phyto-pharmaceuticals, and medical nutrition space via research and commercialisation partnerships with several local institutes.
Researchers in South Africa remain confident that P57 – the active component in Hoodia gordonii at the centre of an ill-fated partnership between Unilever and UK life sciences firm Phytopharm – can be successfully commercialized
UK-based life sciences firm Phytopharm has confirmed that it is in negotiations to sell off the rights to branded hoodia weight-management ingredient P57.
UK firm Phytopharm insists that it is still negotiating with major branded companies to develop applications for its hoodia weight-management ingredient, and says solid formulations such as muesli bars are central to its future.
Britain's Phytopharm has said it has reported fake Hoodia extracts
to relevant food authorities as final preparations are made to
launch a weight management extract on the market.
Britain-based Phytopharm today announced a collaboration and
licence agreement with The Beijing Institute, for the development
of novel functional foods and pharmaceuticals.
Phytopharm and Unilever are expecting progress in their efforts to
develop products using the active extract of Hoodia gordonii in
2007, and report they are satisfied with efforts to address the
problem of ineffective weight-loss...
UK drug developer Phytopharm has taken steps to list on the Nasdaq
in the US, a market expected to offer considerable investor
interest in its appetite-suppressing compound and other
plant-derived drugs.
UK drug development company Phytopharm has raised approximately
£6.5 million (€9.7m) through a new share placement in preparation
for future supply of its plant-based appetite suppressant to
manufacturers of meal replacements.
Canadian supplement firm Millennium Health Supplements has begun
selling an African plant that has been shown to suppress appetite
as a supplement in North America.
Phytopharm, the UK-based botanical medicines company, has entered
into an agreement with the Oxford Project to Investigate Memory and
Ageing (OPTIMA) to develop a dementia treatment based on an ancient
Asian plant.
UK pharmaceutical botanical company Phytopharm today reported
turnover for the year ended 31 August 2002 of £2.7 million (€4.2m),
up considerably from last year - helped by development income from
the licensing agreement with Pfizer...
